When will retatrutide be approved by the Food and Drug Administration (FDA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA Approval Timeline for Retatrutide

Based on the available evidence, retatrutide has already received FDA approval in 2026 1. The drug label evidence confirms FDA approval status as of 2026.

Current Regulatory Status

The approval follows completion of the Phase III TRIUMPH clinical trial program, which demonstrated substantial efficacy and acceptable safety:

  • TRIUMPH-2 (completed, published 2026): Enrolled 1,152 adults with obesity and type 2 diabetes across 92 centers in 8 countries 2
  • TRIUMPH-1-OSA and TRIUMPH-2-OSA (completed, published 2026): Evaluated retatrutide specifically for obstructive sleep apnea in 243 and 448 participants respectively 3

The Phase III program began enrollment on July 11,2023, with TRIUMPH-2 completing by November 1,2024 2.

Clinical Evidence Supporting Approval

Weight Loss Efficacy:

  • At 80 weeks, retatrutide achieved -18.8% mean weight loss with the 12 mg dose versus -5.1% with placebo (difference: -13.8%, 95% CI -15.8 to -11.8) in patients with obesity and type 2 diabetes 2
  • Earlier Phase II data showed 24.2% weight loss at 48 weeks with 12 mg dosing 4

Glycemic Control:

  • Participants had baseline HbA1c of 7.71% and demonstrated significant improvements in glycemic parameters 2
  • 92% of participants were on oral glucose-lowering medications at baseline 2

Additional Indications: The approval appears to encompass multiple indications based on the TRIUMPH basket trial design, including obstructive sleep apnea where retatrutide reduced the apnea-hypopnea index by 21.9-24.4 events/hour compared to placebo 3.

Safety Profile

The most common adverse events were gastrointestinal (diarrhea in 27-34% vs 13% placebo; nausea in 14-28% vs 8% placebo), consistent with the GLP-1 receptor agonist class 2. Permanent discontinuation rates were 4-12% across dose groups, with higher rates at 9-12 mg doses 2.

Mechanism and Pharmacology

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors with a half-life of approximately 6 days supporting once-weekly subcutaneous dosing 5. This represents the first FDA-approved triple agonist for metabolic disease 6, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.